Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia

Journal of Psychopharmacology

Volumn 29, Issue 4, 2015, Pages 383-389

  Takase, Masayuki ^a   Kanahara, Nobuhisa ^b   Oda, Yasunori ^a   Kimura, Hiroshi ^a   Watanabe, Hiroyuki ^b   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Antipsychotic; dopamine partial agonist; dopamine supersensitivity; schizophrenia; tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG EFFECT; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME; DOSE RESPONSE; METABOLISM; MIDDLE AGED; PARTIAL AGONISM; PSYCHOSES, SUBSTANCE-INDUCED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84924993304     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115570083     Document Type: Article

References (24)

1. Adan-Manes J, Garcia-Parajua P. Aripiprazole in combination with other antipsychotic drugs worsen psychosis. J Clin Pharm Ther. 2009 ; 34: 245-246
2. Azekawa T, Ohashi S, Itami A. Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr Dis Treat. 2011 ; 7: 691-695
3. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology (Berl). 2003 ; 166: 391-399
4. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991 ; 5: 21-33
5. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008 ; 77: 69-77
6. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978 ; 135: 1409-1410
7. DeQuardo JR. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?. J Clin Psychiatry. 2004 ; 65: 132-133
8. Fallon P, Dursun SM. A naturalistic controlled study of relapsing schizophrenic v patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol. 2011 ; 25: 755-762
9. Fallon P, Dursun S, Deakin B. Drug-induced supersensitivity psychosis revisited: Characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012 ; 2: 13-22
10. Gorwood P. Meeting everyday challenges: Antipsychotic therapy in the real world. Eur Neuropsychopharmacol. 2006 ; 16: S156 - S162
11. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013 ; 33: 398-404
12. Kim CY, Chung S, Lee JN, et al. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2009 ; 24: 181-188
13. Kirkpatrick B, Alphs L, Buchanan RW. The concept of supersensitivity psychosis. J Nerv Ment Dis. 1992 ; 180: 265-270
14. Lin HC, Chong MY, Lee Y, et al. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med J. 2009 ; 32: 409-416
15. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatr Research. 2008 ; 161: 235-247
16. Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Prim Care Companion J Clin Psychiatry. 2009 ; 11: 147-154
17. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006 ; 114: 3-13
18. Pae CU. Supersensitivity psychosis and aripiprazole tapering. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 748-749
19. Pae CU, Chiesa A, Mandelli L, et al. Predictors of early worsening after switch to aripiprazole: A randomized, controlled, open-label study. Clin Drug Investig. 2010 ; 30: 187-193
20. Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009 ; 19: 562-570
21. Tadokoro S, Okamura N, Sekine Y, et al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2012 ; 38: 1012-1020
22. Tadori Y, Forbes RA, McQuade RD, et al. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 ; 607: 35-40
23. Takeuchi H, Uchida H, Suzuki T, et al. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study. J Clin Psychopharmacol. 2009 ; 29: 394-395
24. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care. 2002 ; 40: 630-639